Viewing Study NCT00225303


Ignite Creation Date: 2025-12-24 @ 7:37 PM
Ignite Modification Date: 2025-12-28 @ 6:54 PM
Study NCT ID: NCT00225303
Status: COMPLETED
Last Update Posted: 2011-05-19
First Post: 2005-09-12
Is NOT Gene Therapy: True
Has Adverse Events: False

Brief Title: TMC125-C227: A Phase II Randomized, Active-Controlled, Open Label Trial to Investigate the Efficacy and Tolerability of TMC125 in HIV-1 Infected Subjects, Who Are PI-Naive and With Documented Genotypic Evidence of NNRTI Resistance From Previous NNRTI Use
Sponsor: Tibotec Pharmaceuticals, Ireland
Organization:

Study Modules

Identification Module Status Module Sponsor Collaborators Module Description Module Conditions Module Design Module Arms Interventions Module Outcomes Module Eligibility Module Contacts Locations Module References Module